Advertisement

Radiochemistry

, Volume 60, Issue 6, pp 625–633 | Cite as

Intricacies of the Determination of the Radiochemical Purity of 68Ga Preparations: Possibility of Sorption of Ionic 68Ga Species on Reversed-Phase Columns

  • A. A. LarenkovEmail author
  • A. Ya. Maruk
  • G. E. Kodina
Article
  • 11 Downloads

Abstract

The results of studying 68Ga radiopharmaceuticals using various TLC and HPLC procedures are compared. The data obtained reliably show that a part of 68Ga ionic species are irreversibly (under definite conditions) sorbed onto chromatographic columns packed with С18 reversed phase. The loss of 68Ga ionic species in the analysis can reach 90%. The 68Ga loss increases with an increase in pH of the preparation. At pH 2.5–3.0, the total loss of 68Ga ionic species on the chromatographic column does not exceed 15%. At pH 4.0, it is 65 ± 7% on the average, and at pH 6.0 it reaches 87 ± 8%. This effect should be taken into account in analysis of any 68Ga radiopharmaceuticals.

Keywords

radiopharmaceuticals gallium-68 radiochemical purity quality control chromatography HPLC complexation sorption 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rösch, F. and Riss, P.J., Curr. Top. Med. Chem., 2010, vol. 10, p. 1633.CrossRefGoogle Scholar
  2. 2.
    Larenkov, A.A., Bruskin, A.B., and Kodina, G.E., Med. Radiol. Radiats. Bezopasn., 2011, vol. 56, no. 5, p. 56.Google Scholar
  3. 3.
    Larenkov, A.A. and Kodina, G.E., Med. Radiol. Radiats. Bezopasn., 2017, vol. 62, no. 6, p. 58.CrossRefGoogle Scholar
  4. 4.
    Kilian, K., Rep. Pract. Oncol. Radiother., 2014, vol. 19, p. 13.CrossRefGoogle Scholar
  5. 5.
    Velikyan, I., Theranostics, 2014, vol. 4, no. 1, p. 47.CrossRefGoogle Scholar
  6. 6.
    Breeman, W.A.P., de Blois, E., Chan, H.S., et al., Semin. Nucl. Med., 2011, vol. 41, no. 4, p. 314.CrossRefGoogle Scholar
  7. 7.
    Bauwens, M., Chekol, R., Vanbilloen, H., et al., Nucl. Med. Commun., 2010, vol. 31, no. 8, p. 753.CrossRefGoogle Scholar
  8. 8.
    Kubícek, V., Havlícková, J., Kotek, J., et al., Inorg. Chem., 2010, vol. 49, no. 23, p. 10 960.CrossRefGoogle Scholar
  9. 9.
    Larenkov, A.A. and Maruk, A.Ya., Int. J. Chem., Mol., Nucl., Mater. Metall. Eng., 2016, vol. 10, no. 9, p. 1212. DOI: 10.5281/zenodo.1126784.Google Scholar
  10. 10.
    Larenkov, A.A. and Maruk, A.Ya., Endocrine Abstr., 2016, vol. 47, p. OC44. DOI:10.1530/endoabs.47.OC44.Google Scholar
  11. 11.
    European Directorate for the Quality of Medicines & Healthcare (EDQM). Gallium (68Ga) Edotreotide Injection 2482, European Pharmacopoeia 8.0, 2013, p. 1062.Google Scholar
  12. 12.
    Larenkov, A.A., Bruskin, A.B., and Kodina, G.E., J. Radioanal. Nucl. Chem., 2015, vol. 305, no. 1, p. 147.CrossRefGoogle Scholar
  13. 13.
    Larenkov, A.A., Bruskin, A.B., and Kodina, G.E., Radiochemistry, 2014, vol. 56, no. 1, pp. 57–65.CrossRefGoogle Scholar
  14. 14.
    Vis, R., Lavalaye, J., and van de Garde, E.M., EJNMMI Res., 2015, vol. 5, no. 27, pp. 1–7. https://doi.org/10.1186/s13550-015-0105-3.Google Scholar
  15. 15.
    Hacht, B., Open Sci. J., 2016, vol. 1, no. 1, p. 1.CrossRefGoogle Scholar
  16. 16.
    Hacht, B., Bull. Korean Chem. Soc., 2008, vol. 29, no. 2, p. 372.CrossRefGoogle Scholar
  17. 17.
    Wood, S.A. and Samson, I.M., Ore Geol. Rev., 2006, vol. 28, p. 57.CrossRefGoogle Scholar
  18. 18.
    Mann, K. and Swanson, C.L., Anal. Chem., 1961, vol. 33, no. 3, p. 459.CrossRefGoogle Scholar
  19. 19.
    Martins, A.F., Prata, M.I.M., Rodrigues, S.P.J., et al., Contrast Media Mol. Imag., 2013, vol. 8, no. 3, p. 265.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Inc. 2018

Authors and Affiliations

  1. 1.State Research Center Burnasyan Federal Medical Biophysical CenterFederal Medical Biological Agency of RussiaMoscowRussia

Personalised recommendations